Clinical Trial Update: Vyxeos® With Clofarabine for Pediatric AML [Phase 1]

View source ↗

Summary

Phase 1 trial update of Vyxeos with Clofarabine for relapsed or refractory pediatric acute myeloid leukemia; study currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clofarabine (clofarabine)
• Vyxeos (CPX-351)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Relapsed Pediatric AML, Refractory Pediatric AML | Phase 1 | Status: RECRUITING